Celgene Co. (NASDAQ:CELG)‘s stock had its “outperform” rating reiterated by BMO Capital Markets in a research report issued on Tuesday. They currently have a $152.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 30.16% from the stock’s current price.

Several other research firms have also recently weighed in on CELG. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, January 26th. Mizuho set a $130.00 price objective on shares of Celgene and gave the company a “buy” rating in a research report on Sunday, February 19th. Robert W. Baird restated an “outperform” rating and set a $162.00 price objective on shares of Celgene in a research report on Wednesday, April 19th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $148.00 price objective (up previously from $141.00) on shares of Celgene in a research report on Monday, January 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $159.00 price objective on shares of Celgene in a research report on Tuesday, January 24th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $138.89.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) traded up 0.03% during mid-day trading on Tuesday, hitting $116.78. 2,557,459 shares of the company’s stock were exchanged. The stock has a market cap of $91.18 billion, a PE ratio of 43.85 and a beta of 1.74. Celgene has a 12 month low of $94.42 and a 12 month high of $127.64. The stock’s 50 day moving average price is $121.62 and its 200-day moving average price is $119.73.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.21. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3.04 billion. During the same period in the prior year, the company posted $1.32 EPS. The business’s revenue for the quarter was up 17.8% compared to the same quarter last year. Equities analysts expect that Celgene will post $7.28 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/27/celgene-co-celg-receives-outperform-rating-from-bmo-capital-markets.html.

In other news, insider Rupert Vessey sold 4,000 shares of Celgene stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total value of $497,680.00. Following the completion of the sale, the insider now directly owns 778 shares in the company, valued at $96,798.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 14,033 shares of Celgene stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the completion of the sale, the director now owns 73,109 shares of the company’s stock, valued at $9,053,087.47. The disclosure for this sale can be found here. Insiders sold 27,283 shares of company stock valued at $3,382,386 over the last ninety days. Corporate insiders own 0.97% of the company’s stock.

Several hedge funds have recently made changes to their positions in CELG. Boston Family Office LLC raised its stake in shares of Celgene by 1.4% in the third quarter. Boston Family Office LLC now owns 147,800 shares of the biopharmaceutical company’s stock worth $15,450,000 after buying an additional 2,025 shares in the last quarter. Klingenstein Fields & Co. LLC raised its stake in shares of Celgene by 0.6% in the third quarter. Klingenstein Fields & Co. LLC now owns 144,361 shares of the biopharmaceutical company’s stock worth $15,090,000 after buying an additional 859 shares in the last quarter. Hikari Power Ltd raised its stake in shares of Celgene by 6.9% in the third quarter. Hikari Power Ltd now owns 76,400 shares of the biopharmaceutical company’s stock worth $7,985,000 after buying an additional 4,900 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Celgene by 0.5% in the third quarter. Arizona State Retirement System now owns 190,918 shares of the biopharmaceutical company’s stock worth $19,957,000 after buying an additional 900 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Celgene by 14.1% in the third quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock worth $1,664,222,000 after buying an additional 1,967,645 shares in the last quarter. Hedge funds and other institutional investors own 77.68% of the company’s stock.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

12 Month Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.